Pristimerin (Pris) is triterpenoid compound with many biological effects. Until now, nothing is known about its effect on doxorubicin (DOX)-induced cardiotoxicity. Hence, this study investigated the impact of Pris on DOX-induced cardiotoxic effects.
(2019). Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis. Cardiovascular Research Prove Journal, 3(1), -. doi: 10.21608/cvrepj.2019.351824
MLA
. "Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis", Cardiovascular Research Prove Journal, 3, 1, 2019, -. doi: 10.21608/cvrepj.2019.351824
HARVARD
(2019). 'Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis', Cardiovascular Research Prove Journal, 3(1), pp. -. doi: 10.21608/cvrepj.2019.351824
VANCOUVER
Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis. Cardiovascular Research Prove Journal, 2019; 3(1): -. doi: 10.21608/cvrepj.2019.351824
)
View on SCiNiTO